Entrada Therapeutics advances ENTR — 601 — 44 Phase 1/2 DMD trial to 18 mg/kg Cohort 3 after DMC review

Entrada Therapeutics moved its ELEVATE-44-201 study into Cohort 3 at the top 18 mg/kg dose following a safety committee review. The committee reviewed available safety and drug-behavior data from eight Cohort 2 participants, supporting continued dose escalation. The trial is evaluating ENTR-601-44 in Duchenne muscular dystrophy patients with mutations suitable for exon 44 skipping. Cohort 1 open-label results are expected by year-end 2026; Cohort 2 data are scheduled for Q1 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief via (Ref. ID: 202610140700PRIMZONEFULLFEED9845114) on October 14, 2026, and is solely responsible for the information contained therein. (C)